Clinical Trial Update: A Pharmacokinetic Study of Eltrombopag 50 Milligram (mg) in Healthy Volunteers Under Fasting Conditions [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study of eltrombopag 50 mg in healthy volunteers under fasting conditions has completed. The sponsor is GlaxoSmithKline.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis of the Liver

Drugs mentioned

• Eltrombopag (eltrombopag)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cirrhosis, Liver | Phase 1 | Status: COMPLETED